Drug intelligence / Profile preview

MPY4

Development stage: Preclinical
Modality: Small Molecules

Overview

MPY4 is an experimental **small-molecule amino-pyrimidine-curcumin analog** reported in a medicinal chemistry study aimed at improving the poor stability and bioavailability of curcumin for oncology applications. It appears to be one of a series of novel pyrimidine-curcumin derivatives synthesized and characterized for acid-base behavior, solution stability, and antiproliferative activity in prostate and colorectal cancer cell lines. Based on the available source, MPY4 is a preclinical research compound rather than a clinically developed pharmaceutical candidate; its precise molecular target and mechanism of action have not been established, but it is being investigated as a chemically stabilized curcumin-inspired antineoplastic agent.

Other names: amino-pyrimidine-curcumin analog MPY4pyrimidine-curcumin derivative MPY4

Beyond the preview

Go deeper on MPY4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MPY4.

Explore the full profile